论文部分内容阅读
树突状细胞(DC)是现今被认为最具潜能的专职抗原呈递细胞。应用不同方法在体内诱导细胞毒T细胞(CTL)来识别肿瘤相关抗原的肿瘤免疫治疗研究已有报告。然而,在体内免疫治疗的有效性可能仅限制在局部或系统抑制CTL产生和功能。为了检测LPS刺激人单核细胞的DC来抑制自体CD4+CD25+T细胞能力,使用HLAA2限制性p53264-272肽作为肿瘤抗原,用LPS(DCLPS+)或不用LPS(DCLPS-)产生的DC分别与自体T细胞共同培养。结果显示:在DCLPS+活化的T细胞的CD4+CD25+T细胞群比DCLPS-活化的T细胞要低。这个结果提示,DCLPS+与CD4+CD25+T细胞群有关联,而且这种特性可能是由于T细胞对肿瘤相关抗原的调节作用。
Dendritic cells (DCs) are by far the most promising full-time antigen presenting cells. Tumor immunotherapy using different methods to induce cytotoxic T cells (CTLs) in vivo to recognize tumor-associated antigens has been reported. However, the effectiveness of in vivo immunotherapy may be limited to local or systemic inhibition of CTL production and function. To test the ability of LPS to stimulate human monocytic DCs to inhibit autologous CD4 + CD25 + T cells, DCs generated either with LPS (DCLPS +) or without LPS (DCLPS-) using the HLAA2-restricted p53264-272 peptide as a tumor antigen were used with Autologous T cells co-cultured. The results showed that the population of CD4 + CD25 + T cells in DCLPS + activated T cells was lower than DCLPS-activated T cells. This result suggests that DCLPS + is associated with a population of CD4 + CD25 + T cells, and this property may be due to the regulatory effect of T cells on tumor-associated antigens.